Arundathi Jayatilleke, MD
Dec 4th, 2021 - Arundathi Jayatilleke, MD Many people with rheumatoid arthritis (RA) have concomitant hand osteoarthritis (OA). This Swiss cohort study by Lechtenboehmer et al 1 using a longitudinal registry of RA patients examined characteristics of RA patients who had progression of radiographic hand OA.
Vinod Chandran, MBBS, MD, DM, PhD
Dec 4th, 2021 - Vinod Chandran, MBBS, MD, DM, PhD Research published in November has provided us with insights on the impact of psoriatic arthritis (PsA) as well as treatment outcomes. Although PsA often affects women of child-bearing age, data on pregnancy outcomes in PsA is scarce.
Dec 4th, 2021 - The combination of ribociclib (Kisqali) and everolimus (Afinitor) elicits responses in patients with advanced dedifferentiated liposarcoma (DDLPS) and offers a tolerable safety profile, according to Margaret von Mehren, MD, who added that these responses have not previously been seen in this patient population with CDK4 inhibitors. The phase 2 SAR-096 trial (NCT03114527) met its primary end ...
Dec 3rd, 2021 - Manojkumar Bupathi, MD, MS, medical oncologist, Rocky Mountain Cancer Centers, discusses the evolving treatment landscape of bladder cancer. Although unmet needs exist in bladder cancer, the integration of maintenance therapy has improved survival outcomes for patients, Bupathi says. However, it remains unknown why some patients do not derive sufficient responses to available therapy. As suc...
Dec 3rd, 2021 - High altitude hurt the quality of chest compressions from trained rescuers without them realizing it, experiments showed. At simulated altitudes of 200, 3,000, or 5,000 meters in a hypobaric chamber, helicopter EMS personnel started out with optimal chest compressions on manikins, but gradually lost both the depth in their compressions and the proper pacing of effective compressions over time, ...
The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory about increased influenza A(H3N2) activity that could mark the beginning of the 2021-2022 influenza season.
Dec 3rd, 2021 - Progress continued on a vaccine against respiratory syncytial virus (RSV) for older adults, while the country experienced a resurgence in infections among young children this year that caused the CDC to issue a Health Advisory on the illness. Vaccine Development in Older Adults Continues to Accelerate Janssen's adenoviral vector vaccine against RSV in older adults was safe and effective, partic...
Joan Merrill, MD
Dec 3rd, 2021 - Dr Joan Merrill, of the Oklahoma Medical Research Foundation in Oklahoma City, reviews updates on several treatment options for systemic lupus erythematosus that were presented at the 2021 ACR Convergence. Dr Merrill begins by sharing data from a phase 2 study in which she and her colleagues investigated the efficacy and safety data for iberdomide.
Dec 2nd, 2021 - The shift away from chemotherapy as a standard treatment for patients with HER2-positive breast has continued with the incorporation of de-escalated therapies into the treatment paradigm, according to Deborah L. Toppmeyer, MD. Allowing patients to avoid potential adverse events associated with chemotherapy has been a key benefit of expanded treatment options, Toppmeyer said. She added that the...
Dec 2nd, 2021 - Adding the angiogenesis inhibitor bevacizumab (Avastin) to osimertinib (Tagrisso) failed to slow progression of advanced EGFR-mutant non-small-cell lung cancer (NSCLC) that had progressed on prior anti-EGFR therapy, a randomized trial showed. Median progression-free survival (PFS) increased from 12.3 months with osimertinib alone to 15.4 months with the combination, but the difference did not a...
Dec 2nd, 2021 - Note that some links may require registration or subscription. Donald Trump tested positive for COVID-19 days before the first presidential debate against Joe Biden, according to his chief of staff at the time and other former aids; Trump denounced the claims as "fake news." (Washington Post) In order to track travel-related Omicron cases, the CDC ordered airlines to share data on passengers ar...
Dec 1st, 2021 - Significant progress with rapidly evolving therapies, including blinatumomab (Blincyto), inotuzumab ozogamicin (Besponsa), and chimeric antigen receptor (CAR) T-cell therapy, has been made to extend the median overall survival (OS) and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Antibody-based therapies and CAR T-cell therapies are not mut...
Dec 1st, 2021 - Multiple Myeloma is a clonal plasma cell neoplasm characterized by bone lesions, renal impairment, cytopenias, and immunodeficiency. Despite significant therapeutic advancements in the past 2 decades that have resulted in improved survival, myeloma remains an incurable disease. The immune environment in which the cancer cells thrive is known to be a key player in the evolution of monoclonal gam...
Dec 1st, 2021 - A web-based system developed by British academic researchers was unveiled Wednesday that illustrates, in simple graphical form, how much various mitigation measures reduce the risk of SARS-CoV-2 transmission in different situations. The system depicts two people, one infected on the left, and one uninfected on the right. Connecting them are shaded arrows representing different potential transmi...
FluView Activity Update (Key Flu Indicators)
Dec 1st, 2021 - Retifanlimab (INCMGA 0012) demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer, according to data from the phase 1 POD1UM-101 trial (NCT03059823), presented during the 2021 SITC Annual Meeting.1 At a median follow-up of 8.4 months (range, 1.9-28.3), the ...
Dec 1st, 2021 - Key clinical point: Certolizumab (CTZ) monotherapy seemed as effective as combination therapy with methotrexate (MTX) or leflunomide (LFN) or MTX+LFN in patients with rheumatoid arthritis (RA) who failed previous conventional synthetic disease-modifying antirheumatic drugs (csDMARD) therapy. Major finding: Overall, 63% of patients were in remission or showed low disease activity (LDA) within 3.
Dec 1st, 2021 - Key clinical point: Alvocidib followed by cytarabine and mitoxantrone (ACM) was clinically active and well tolerated in patients with myeloid cell leukemia-1 (MCL-1)-dependent relapsed/refractory (R/R) acute myeloid leukemia (AML). Major finding: The rates of composite complete remission after 1 cycle of ACM therapy were 47%, 21%, 64%, and 52% in patients with R/R AML with MCL-1 <15%, 15% to <3.
Dec 1st, 2021 - Key clinical point: Tumor necrosis factor (TNF)- α inhibitors effectively improved skin, nail, and joint symptoms and quality of life (QoL) in patients with nail psoriasis and concomitant psoriatic arthritis (PsA). Major finding: During the first 3 months, nail psoriasis improved significantly along with improvements in the mean number of swollen joints (SJ), which reduced from 6.
Dec 1st, 2021 - Key clinical point: Upadacitinib led to early and sustained clinically meaningful improvements in patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA) having an inadequate response to nonbiologic disease-modifying antirheumatic drugs (non-bDMARD). Major finding: A greater proportion of patients treated with 15 and 30 mg upadacitinib vs.